background image - desktop
Case Study , Translational Pharmaceutics , Clinical Pharmacology , First-in-Human

Case Study: BioCryst Pharmaceuticals


Request a copy of our case study with BioCryst Pharmaceuticals who were looking for a partner with expertise and experience to provide certainty that the delivery timelines for the program could be achieved

A small biotech company, BioCryst Pharmaceuticals was founded in Birmingham, Alabama. BioCryst is a pharmaceutical company that has stayed true to its commitment to discovering, developing, and delivering treatments to patients that may have an extraordinary impact on their lives. BioCryst Pharmaceuticals specializes in structure-guided small molecule drug design, using detailed knowledge of the structures of active sites of clinically significant enzymes to develop novel agents that interfere with the progression of the disease. Founded in 1986, the company’s development pipeline currently includes inhibitor-based treatment programs for hereditary angioedema (HAE), hemorrhagic fevers, influenza, and gout.

Quotient Sciences was approached to help BioCryst Pharmaceuticals in their development of BCX4161, a promising candidate for the treatment of hereditary angioedema. They took advantage of our Translational Pharmaceutics® platform and First-In-Human program for the development to accelerate their timelines and hit key deadlines. Request a copy of the case study today here.